Background

In recent years, health insurance companies, employers and pharmacy benefit managers (PBMs) have increasingly shifted an ever-greater share of costs for specialty prescription medicines to their patients and beneficiaries. Cost-sharing requirements set by insurers for prescription medicines (such as high coinsurance and deductible amounts) are often uniquely burdensome relative to other types of health care. Oftentimes, pharmaceutical manufacturers offer copayment cards or drug coupons in order to help patients afford the cost of their prescriptions. Such cards or coupons can reduce or eliminate the patient share in payment for medications.

Two new programs known respectively as “co-pay accumulators” and “co-pay maximizers” have recently emerged as forms of utilization management. These programs target specialty drugs for which manufacturers often provide copay assistance. With a co-pay accumulator or co-pay maximizer program in place, a manufacturer’s assistance no longer applies toward a patient’s co-pay or out-of-pocket maximum. This means that patients will experience increased out of pocket costs and take longer to
reach required deductibles. Such utilization management tactics negate the intended benefit of patient assistance programs—and remove a safety net for patients who need expensive specialty medications but cannot afford them. This could lead to poorer health outcomes and potentially higher costs to the health care system.

**Concerns for ASCO Members & the Cancer Community**

There are several concerns with co-pay accumulator and maximizer programs, from both the provider and patient perspective. One area is the lack of transparency involved in the implementation of copayment accumulator and maximizer programs. Co-pay accumulator programs lack transparency and are often implemented without a patient’s knowledge or full understanding of their new “benefit.” Co-pay accumulators could jeopardize outcomes, as patients may decide to forego or discontinue treatment or seek different treatment for non-medical reasons.

From the provider perspective, many ASCO members describe the difficulty and time-consuming process involved in finding financial assistance for their patients. This additional complexity in patient coverage policy will only increase the administrative burden on practice staff, who will now need to understand the nuances of co-pay accumulators and maximizers; as well as help explain to patients why some of the assistance is not helping them to reach their deductible.

**Where ASCO Stands on Co-Pay Accumulators**

ASCO has weighed in on the rising cost of cancer care several times, including position statements on the affordability of cancer drugs and utilization management. ASCO’s Position Statement, *Pharmacy Benefit Managers and Their Impact on Cancer Care* describes concerns with copay accumulator programs. “While they are described as a benefit for patients, these programs in effect prevent patients from reaching their deductibles sooner [...] while increasing cost-sharing for patients.” ASCO believes co-pay accumulator programs shift more healthcare costs away from plan sponsors and employers, and onto patients.

Per the *ASCO Statement on the Impact of Utilization Management Policies for Cancer Drug Therapies*, cost should not be the primary driver of utilization management policies. Policies that attempt to incentivize, force, or coerce patients to accept anti-cancer therapy alternatives that are not recommended by their oncologist can threaten both the outcomes for patients and the well-being of their families or caretakers. Thus, individuals with cancer should have full access to the anti-cancer therapy most appropriate for their disease when used in accordance with current clinical and scientific evidence. Cost-containment strategies should not limit the ability for patients to receive access to appropriate care, or for providers to prescribe such care. They should also be transparent and without conflicts of interest.
For More Information

American Society of Clinical Oncology Position Statement On Addressing the Affordability of Cancer Drugs


American Society of Clinical Oncology Position Statement: Pharmacy Benefit Managers and Their Impact on Cancer Care